The Heart Institute, Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Anat Rec (Hoboken). 2019 Jan;302(1):125-135. doi: 10.1002/ar.23916. Epub 2018 Oct 10.
Epithelial-to-mesenchymal transition (EMT) enables stationary epithelial cells to exhibit migratory behavior and is the key step that initiates heart valve development. Recent studies suggest that EMT is reactivated in the pathogenesis of myxomatous valve disease (MVD), a condition that involves the progressive degeneration and thickening of valve leaflets. These studies have been limited to in vitro experimentation and reliance on histologic costaining of epithelial and mesenchymal markers as evidence of EMT in mouse and sheep models of valve disease. However, longitudinal analysis of cell lineage origins and potential pathogenic or reparative contributions of newly generated mesenchymal cells have not been reported previously. In this study, a genetic lineage tracing strategy was pursued by irreversibly labeling valve endothelial cells in the Osteogenesis imperfecta and Marfan syndrome mouse models to determine whether they undergo EMT during valve disease. Tie2-CreER and Cdh5(PAC)-CreER mouse lines were used in combination with colorimetric and fluorescent reporters for longitudinal assessment of endothelial cells. These lineage tracing experiments showed no evidence of EMT during adult valve homeostasis or valve pathogenesis. Additionally, CD31 and smooth muscle α-actin (αSMA) double-positive cells, used as an indicator of EMT, were not detected, and levels of EMT transcription factors were not altered. Interestingly, contrary to the endothelial cell-specific Cdh5(PAC)-CreER driver line, Tie2-CreER lineage-derived cells in diseased heart valves also included CD45+ leukocytes. Altogether, our data indicate that EMT is not a feature of valve homeostasis and disease but that increased immune cells may contribute to MVD. Anat Rec, 302:125-135, 2019. © 2018 Wiley Periodicals, Inc.
上皮-间质转化(EMT)使静止的上皮细胞表现出迁移行为,是启动心脏瓣膜发育的关键步骤。最近的研究表明,EMT 在黏液瘤性瓣膜病(MVD)的发病机制中被重新激活,这种情况涉及瓣膜小叶的进行性退化和增厚。这些研究仅限于体外实验,并依赖于上皮和间充质标志物的组织化学染色作为 EMT 在瓣膜疾病的小鼠和绵羊模型中的证据。然而,尚未有关于细胞谱系起源的纵向分析以及新产生的间充质细胞的潜在致病或修复贡献的报道。在这项研究中,通过不可逆地标记成骨不全症和马凡综合征小鼠模型中的瓣膜内皮细胞,采用遗传谱系追踪策略来确定它们在瓣膜疾病过程中是否经历 EMT。Tie2-CreER 和 Cdh5(PAC)-CreER 小鼠系与比色和荧光报告基因结合使用,用于内皮细胞的纵向评估。这些谱系追踪实验表明,在成年瓣膜稳态或瓣膜发病过程中没有 EMT 的证据。此外,没有检测到 CD31 和平滑肌α-肌动蛋白(αSMA)双阳性细胞,作为 EMT 的指标,并且 EMT 转录因子的水平没有改变。有趣的是,与内皮细胞特异性的 Cdh5(PAC)-CreER 驱动线相反,患病心瓣膜中的 Tie2-CreER 谱系衍生细胞还包括 CD45+白细胞。总之,我们的数据表明,EMT 不是瓣膜稳态和疾病的特征,而是增加的免疫细胞可能导致 MVD。解剖学记录,302:125-135,2019。©2018 年 Wiley 期刊,公司。